glp-1 egfr cut off TrimRX GLP-1 Receptor Agonists and Diabetic

Allegations of Undisclosed Risks Plaintiffs assert that the manufacturers of Ozempic, Wegovy, Mounjaro, Victoza, Saxenda, Rybelsus, and other GLP-1 agonists failed to adequately warn consumers about the risk of these potentially life-altering side effects

Prevalence of comorbid major depressive disorder in Type 2 diabetes: a meta-analysis of comparative and epidemiological studies

95% CI: 0.75-1.01), it did not reach statistical significance

Furthermore, the relative importance of endogenous GLP-2 versus GLP-1 or glucagon as orchestrators of these chemogenetic responses was not determined and is clearly less important for weight control relative to pharmacological actions of the same peptides

Results show broad benefits with a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions

Final thoughts from a mental health perspective Compared to 2023, the conversation around GLP-1s is more grounded and more complex